南微医学(688029.SH):2025年净利润5.7亿元,同比增长3.05%

Core Viewpoint - The company reported record high revenue and profit for the year 2025, establishing a solid foundation for growth in 2026, despite a challenging external environment [1] Financial Performance - The company achieved total operating revenue of 3.191 billion yuan, an increase of 15.81% compared to the same period last year [1] - The net profit attributable to the parent company's shareholders was 570 million yuan, reflecting a growth of 3.05% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 557 million yuan, up 2.40% from the previous year [1] Growth Drivers - Revenue growth was primarily driven by overseas business and new product launches, even amidst high uncertainty in the external environment and overall industry pressure [1] - The company effectively mitigated short-term pressures from centralized procurement and tariffs through localized marketing, accelerated new product launches, and cost reduction measures [1] - The stability of domestic business also contributed to the overall revenue growth during the reporting period [1]

MTM-南微医学(688029.SH):2025年净利润5.7亿元,同比增长3.05% - Reportify